Background Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-
acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic …

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death
worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow …

The clinical relevance of the anti‐inflammatory properties of beta‐2 agonists remains
contentious possibly due to differences in their molecular structures and agonist activities …

A sensitive, simple and rapid capillary electrophoresis method for the simultaneous
determination of indacaterol and glycopyrronium was developed and validated. The …

Background Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity
and mortality worldwide. A combination of indacaterol maleate with glycopyrronium bromide …

Background: Indacaterol is a novel once-a-day inhaled ultra-long-acting β2-agonist.
Quantitative bioanalysis supports pharmacokinetic and clinical research. The aim of the …

Indacaterol is a recent ultra-long-acting inhaled β2-agonist bronchodilator. The current work
validated an in-house developed high performance liquid chromatography (HPLC)-tandem …

Excessive coughing is a common feature of airway diseases. Different G-protein coupled
receptors, including β2-adrenergic receptors (β2-AR), have been implicated in the molecular …

Two once-daily inhaled bronchodilators, indacaterol and tiotropium, are widely used as first-
line therapy in stable COPD patients. This study was performed to compare the clinical …

Asthma has been recognised as a respiratory disorder for millennia and the focus of
targeted drug development for the last 120 years. Asthma is one of the most common …